Fate Therapeutics (FATE) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Fate Therapeutics (FATE) over the past year, gaining 99.2% versus a gain of 54.7%. Over five years, SRZN leads with a -73.5% price change compared with -96.5% for FATE. Surrozen is the larger company by market cap ($328.7 million vs $255.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | SRZN |
|---|---|---|
| Share price | $2.13 | $27.97 |
| Market cap | $255.22M | $328.75M |
| 1-day change | -0.93% | +11.23% |
| YTD return | +119.39% | +23.76% |
| 1-year return | +54.68% | +99.22% |
| 5-year return | -96.49% | -73.48% |
| EPS (TTM) | $-1.05 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $37.83 |
| 52-week low | $0.95 | $11.39 |
| Distance from 52-week high | -34.06% | -26.06% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +169.48% | +73.04% |
| Average volume | 1.89M | 475.02K |
| Shares outstanding | 119.82M | 11.75M |
| Employees | 161 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed FATE by 44.5 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
FATE vs SRZN FAQ
Which is bigger, Fate Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $255.22M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, FATE or SRZN?
SRZN returned +99.22% over the past 12 months, compared with +54.68% for FATE (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.